---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008712"
form_type: "8-K"
ticker: "XAIR"
cik: "0001641631"
company_name: "Beyond Air, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:32:35.338699+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beyond Air appoints Jeff Myers, M.D., Ph.D. as Chief Medical Officer effective March 27, 2023

## Summary
- Dr. Myers brings ~15 years of biopharmaceutical executive experience and was previously a cardiothoracic surgeon at Massachusetts General Hospital.
- Incumbent CMO Dr. Andrew Colin transitions to Senior Medical Director Global Clinical Leadership.
- Dr. Myers received inducement option for 50,000 shares and inducement RSU for 50,000 shares, vesting over 4 and 5 years respectively.
- Stock awards were approved by independent compensation committee under Nasdaq Listing Rule 5635(c)(4).
- Beyond Air focuses on inhaled nitric oxide via LungFit platform for respiratory conditions and solid tumors through affiliate Beyond Cancer.

## SEC filing metadata
- accession: 0001493152-23-008712
- form_type: 8-K
- ticker: XAIR
- cik: 0001641631
- company_name: Beyond Air, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641631/000149315223008712/0001493152-23-008712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641631/000149315223008712/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008712
- JSON: https://secwatch.observer/filing/0001493152-23-008712.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.